Grover Steven A, Lowensteyn Ilka, Joseph Lawrence, Kaouache Mohammed, Marchand Sylvie, Coupal Louis, Boudreau Ghislain
McGill Cardiovascular Health Improvement Program, The McGill University Health Centre, Montreal, Canada.
J Gen Intern Med. 2009 Jan;24(1):33-9. doi: 10.1007/s11606-008-0825-4. Epub 2008 Oct 21.
Hypertension is common among patients with dyslipidemia but is often poorly treated. The objective of this analysis was to evaluate how a decision aid, used by primary care physicians to improve lipid therapy, impacted on the treatment of hypertension.
Data were analyzed from patients enrolled in a randomized trial focusing primarily on the treatment of dyslipidemia. Patients received usual care or a coronary risk profile every three months to monitor the risk reduction following lifestyle changes and/or pharmacotherapy to treat dyslipidemia. Hypertension management was assessed based on a post hoc analysis of individuals whose blood pressure exceeded current national hypertension guidelines.
There were 2,631 subjects who completed the study. Among 1,352 patients without diagnosed hypertension, 30% were above target on at least three consecutive visits. Among 1,279 individuals with known hypertension, 69% were above target on at least two consecutive visits. Overall, patients receiving risk profiles were more likely to receive appropriate antihypertensive therapy (OR = 1.40, 95% CI 1.11-1.78) compared to those receiving usual care. After adjustment for inter-physician variability and potential confounders, the use of the risk profile was associated with an increased likelihood of starting therapy (OR = 1.78, 95% CI 1.06-3.00) or modifying therapy (OR = 1.40, 95% CI 1.03-1.91).
In this clinical trial of dyslipidemia management, inadequately controlled hypertension was common, occurring in nearly 50% of individuals. Ongoing coronary risk assessment was associated with more appropriate blood pressure management. Cardiovascular risk assessment decision aids should be further evaluated in a randomized trial of hypertension therapy.
高血压在血脂异常患者中很常见,但治疗往往不佳。本分析的目的是评估初级保健医生用于改善血脂治疗的决策辅助工具如何影响高血压的治疗。
对主要关注血脂异常治疗的随机试验中纳入的患者数据进行分析。患者每三个月接受常规护理或冠状动脉风险评估,以监测生活方式改变和/或药物治疗血脂异常后风险的降低情况。基于对血压超过当前国家高血压指南的个体进行的事后分析来评估高血压管理情况。
有2631名受试者完成了研究。在1352名未诊断出高血压的患者中,30%在至少连续三次就诊时血压高于目标值。在1279名已知患有高血压的个体中,69%在至少连续两次就诊时血压高于目标值。总体而言,与接受常规护理的患者相比,接受风险评估的患者更有可能接受适当的抗高血压治疗(OR = 1.40,95%CI 1.11 - 1.78)。在调整了医生间差异和潜在混杂因素后,使用风险评估与开始治疗(OR = 1.78,95%CI 1.06 - 3.00)或调整治疗(OR = 1.40,95%CI 1.03 - 1.91)的可能性增加相关。
在这项血脂异常管理的临床试验中,高血压控制不佳很常见,近50%的个体存在这种情况。持续的冠状动脉风险评估与更适当的血压管理相关。心血管风险评估决策辅助工具应在高血压治疗的随机试验中进一步评估。